SCHEMBL6795133

SCHEMBL6795133

COC(=O)c1[nH]nc2c1Cc1ccc(OC)cc1-2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
KDM4E B2RXH2 3/20 0.54
HSD17B10 Q99714 3/20 0.54
ALPL P05186 2/20 0.54
CLK1 P49759 1/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
ATM Q13315 1/20 0.54
PDGFRB P09619 2/20 0.46
TP53 P04637 1/20 0.43
ACHE P22303 1/20 0.43
MAPT P10636 5/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 2/20 0.43
HPGD P15428 2/20 0.43
CHEK1 O14757 5/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795251 0.93 MEN1 (0.63) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL6791583 0.89 MEN1 (0.68) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL6787018 0.86 CHEK1 (0.46) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL6792055 0.81 KDM4E (0.80) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL6799356 0.81 CHEK1 (0.48) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL6787223 0.81 MEN1 (0.80) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL6791196 0.76 KDM4E (0.50) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL4047927 0.75 PDGFRB (0.55) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL4041860 0.73 PDGFRB (0.65) MEN1KMT2AKDM4EHSD17B10ALPL
SCHEMBL4045624 0.72 PDGFRB (0.47) MEN1KMT2ANPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 MEN1 1382/4885KMT2A 1257/4885KDM4E 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.